Rezolute price target raised to $20 from $15 at Maxim

Maxim raised the firm’s price target on Rezolute (RZLT) to $20 from $15 and keeps a Buy rating on the shares. The firm notes the shifting regulatory environment at FDA which, while inducing challenges for some drug categories, seems to have a more favorable view for rare disease, the analyst tells investors in a research note. Rezolute shares have also been rallying since late May stemming from multiple factors, initially with the completion of enrollment for the Phase 3 study of ersodetug in congenital hyperinsulinism announced on May 28, the firm added.